Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Axcella Health Inc. (AXLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.3300-0.0100 (-0.43%)
At close: 04:00PM EDT
3.0000 +0.67 (+28.76%)
After hours: 04:53PM EDT
Advertisement

Axcella Health Inc.

840 Memorial Drive
3rd Floor
Cambridge, MA 02139
United States
857 320 2200
https://www.axcellahealth.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees59

Key Executives

NameTitlePayExercisedYear Born
Mr. William R. Hinshaw Jr.Pres, CEO & Director830.23kN/A1969
Dr. Alison D. Schecter M.D.Pres of Strategy & Operations525.53kN/A1964
Mr. Laurent ChardonnetConsultant415kN/A1965
Mr. Robert W. CraneSr. VP & CFON/AN/A1959
Dr. Paul Fehlner J.D., Ph.D.Sr. VP, Chief Legal Officer & Corp. Sec.N/AN/A1964
Ms. Virginia R. DeanSr. VP & Chief People OfficerN/AN/A1966
Dr. Larry BellGlobal Head of Regulatory Affairs & Pharmacovigilance and Sr. VPN/AN/AN/A
Dr. Margaret James Koziel M.D.Sr. VP & Chief Medical OfficerN/AN/A1960
Mr. Dan KirbySr. VP of Strategic OperationsN/AN/AN/A
Mr. Karim Azer Ph.D.VP of Systems Biology & DiscoveryN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Corporate Governance

Axcella Health Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement